(NASDAQ)
199.88
-10.16   (-4.84%)
After Hours: 201.61 +1.73 (+0.87%)
Volume (24h) Market Cap. Day Range 52w Range
4.03M 14.23B 199.01 - 220.20 32.30 - 220.20
Jan-14-21 03:11AM With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeBarrons.com
01:22AM CRISPR Therapeutics Has Soared in Just a Few Weeks - What to Do NowTheStreet.com
Jan-12-21 01:24AM Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301Zacks
Jan-11-21 08:02AM The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex PharmaceuticalsZacks
Jan-08-21 09:01AM CRISPR Gene Editing Stocks Up After Intellia's Pipeline UpdateZacks
Jan-07-21 04:24AM Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
02:33AM Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
Jan-07-21 10:38AM Cathie Put the Wood to Wall Street: TSLA, SQ, ROKU, CRSP, BIDUZacks
08:42AM 3 Biotech Technological Developments to Watch Out For in 2021Zacks
Jan-06-21 02:25AM CRISPR Therapeutics Is Still Looking StrongTheStreet.com
11:00AM A New Gene-Editing Technique May Be Able to Help Children Who Prematurely AgeBarrons.com
Jan-01-21 02:42AM 10 Best Stocks To Buy and Hold For 5 Years According To ARK’s Cathie WoodInsider Monkey
Dec-29-20 12:27PM Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayMotley Fool
Dec-23-20 07:29AM 12 Best Genomic Stocks to Buy NowInsider Monkey
Dec-22-20 03:00AM Cutting Edge CRISPR Therapeutics Has Cut a Path HigherTheStreet.com
10:01AM Return On Capital Employed Overview: CRISPR TherapeuticsBenzinga
Dec-22-20 09:48AM 5 Medical Outperformers That Might Lose Steam in 2021Zacks
Dec-21-20 04:24AM Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
12:43PM Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
Dec-21-20 12:12PM Why Editas Medicine Stock Is Skyrocketing TodayMotley Fool
08:43AM 3 Biotech Stocks That Could Explode Higher in 2021Motley Fool
Dec-15-20 07:03AM Where Will CRISPR Therapeutics Be in 10 Years?Motley Fool
Dec-14-20 08:00AM CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIVGlobeNewswire
Dec-13-20 06:45AM If You Have $1,000 and 5 Years to Wait, Buy These 2 Stocks NowMotley Fool
02:04AM Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In GrowthSimply Wall St.
Dec-12-20 03:39AM Watch Out bluebird bio, CRISPR Is on Your HeelsMotley Fool
Dec-10-20 02:03AM CRISPR Gene Editing: Owning the Future of MedicineZacks
01:45AM Is CRISPR Therapeutics Heading for $170?Motley Fool
Dec-10-20 12:47PM Editas (EDIT) Submits Application to Start Study on EDIT-301Zacks
Dec-09-20 11:27AM Why Editas Medicine Stock Is Rising for a Third Consecutive DayMotley Fool
Dec-08-20 04:45AM The Latest Lap in Bluebird’s and Crispr’s Race to Cure Sickle CellBarrons.com
08:44AM Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock?Zacks
Dec-07-20 04:20AM Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily
11:58AM Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily
Dec-07-20 11:23AM Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily
10:06AM Here Are The Winners Of This Year's Biggest Blood Cancer MeetingInvestor's Business Daily
Dec-07-20 09:19AM CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001Zacks
Dec-05-20 12:30PM CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of MedicineGlobeNewswire
Dec-01-20 09:00AM CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta ThalassemiaGlobeNewswire
Nov-24-20 08:00AM CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewswire
Nov-21-20 06:33AM Is Gene Editing Already Leaving CRISPR Therapeutics Behind?Motley Fool
Nov-20-20 09:17AM Volatility May Continue, But CRISPR Stock Remains a BuyInvestorPlace
Nov-16-20 08:00AM CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare ConferenceGlobeNewswire
Nov-14-20 05:24AM 3 Best Biotech Stocks to Buy Right NowMotley Fool
Nov-07-20 07:04AM Got $1,000? You Could Double Your Money by Investing in These 2 BiotechsMotley Fool
Nov-04-20 04:17AM Why This Gene-Editing Player Just Outpaced Bullish Biotech StocksInvestor's Business Daily
03:16AM Why This Gene-Editing Player Just Outpaced Bullish Biotech StocksInvestor's Business Daily
Nov-04-20 02:11AM CRISPR and Vertex Release Additional Data for Blood Disease TreatmentMotley Fool
09:15AM CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and ExpositionGlobeNewswire
Nov-02-20 07:34AM Despite Recent Bad News, Here's Why CRISPR Is Primed to ExplodeMotley Fool
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:    |  Volume (24h):